4.6 Review

Challenges in Antimalarial Drug Treatment for Vivax Malaria Control

Journal

TRENDS IN MOLECULAR MEDICINE
Volume 21, Issue 12, Pages 776-788

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2015.10.004

Keywords

-

Funding

  1. National Institutes of Health NIAID grant [R01 434 A103328]

Ask authors/readers for more resources

Plasmodium vivax is the most widespread human malaria parasite, but has received much less attention than Plasmodium falciparum during the past 50 years of research. Plasmodium vivax was historically seen as causing only benign disease, but this view has recently changed, with increased recognition of the burden of vivax malaria, as well as numerous case reports of severe malaria or death caused by this parasite. The complexity of P. vivax biology is characteristic of specific features of the parasite, and recent years have seen major progress in our understanding of this complexity. In this review, we analyze the latest advances in the field, describing the constraints that the unique features of P. vivax place on drug treatments aimed at controlling or eliminating it.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available